nach oben

Erschienen in:

01.12.2007 | Lab Investigation-Human/Animal Tissue

Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma

verfasst von: Jean-François Mineo, Anne Bordron, Marc Baroncini, Claude-Alain Maurage, Carole Ramirez, Rose-Mary Siminski, Christian Berthou, Phong Dam Hieu

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

Anti-Human Epithelial Receptor Type 2 (HER2) antibodies have the ability to induce in vitro apoptosis of glioblastoma (GBM) cells. This study was designed to evaluate the variability of HER2 expression in GBM and its role as a possible prognosis factor.

Methods

Data of 57 patients with GBM and 16 patients with grade III gliomas were retrospectively analyzed. The expression of HER2 was determined by immunohistochemistry and intensity was noted from 0+ to 3+. We compared the HER2 expression in de novo GBM and in GBM resulting from anaplastic transformation of low-grade glioma (“secondary GBM”). Statistical analysis was performed using univariate analysis and the Kaplan–Meier method.

Findings

All GBM expressing highly HER2 (2+ and 3+) were de novo GBM. All secondary GBM expressed HER2 with low intensity (0+ and 1+). Survival time was significantly longer when HER2 expression was low (Log Rank test P = 0.04). The patterns of HER2 expression were similar between grade III gliomas and secondary GBM.

Conclusions

To our best knowledge, our study showed for the first time a significant association between HER2 expression and the type of GBM, with subsequent influence on survival rate. GBM with low-HER2 expression are more likely to be secondary GBM, carrying a better prognosis than de novo GBM.

Kleihues P, Cavenee WK (eds) (2000) Tumours of the nervous central system. Pathology and genetics. World health organization of tumours. IARC Press, Lyon, pp 55–69

Mineo JF, Quintin-Roue I, Lucas B, Buburuzan V, Besson G (2002) Glioblastomas: clinical study and prognosis factors. Neurochirurgie 48:500–509PubMed

Ohgaki H, Kleihues P (2005) Epidemiology and etiology of gliomas. Acta neuropathol 109:93–108PubMedCrossRef

Rainov N, Dobberstein K, Bahn H, Holzhausen H, Lautenschlager C, Heidecke V, Burkert W (1997) Prognosis factors in malignant glioma: influence of the overexpression of oncogene and tumor suppressor gene products on survival. J Neurooncol 35:13–28PubMedCrossRef

Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, Demonte F, Lang FF, McCutheon IE, Hassenbuch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extend of resection of resection and survival. J Neurosurg 95:190–198PubMed

Mineo JF, Bordron A, Ramirez C, Baroncini M, Maurage CA, Blond S, Dam Hieu P (2007) Prognosis factors of Glioblastoma multiforme: a multivariate analysis in 340 patients. Acta Neurochir 149(3):245–253CrossRef

Devaux BC, O’Fallon JR, Kelly PJ (1993) Resection, biopsy and survival in malignant glial neoplasm. J Neurosurg 78:767–775PubMed

Hegi ME, Diserens AC, Gorlia T, Hamou MF, De Tribolet N, Weller M, Kros JM, Hainfeller JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross G, Janser RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003PubMedCrossRef

Stark A, Nabavi A, Mehdorn HM, Blömer U (2005) Glioblastoma multiforme-report of 267 cases treated at a single institution. Surg Neurol 63:162–169PubMedCrossRef

10.

Koka V, Potti A, Forseen SE, Pervez H, Fraiman GN, Koch M, Levitt R (2003) Role of HER-2/neu overexpression and clinical determinant of early mortality in glioblastoma multiforme. Am J Clin Oncol 26:332–335PubMedCrossRef

11.

Potti A, Forseen SE, Koka VK, Pervez H, Koch M, Fraiman GN, Mehdi SA, Levitt R (2004) Determination of HER/neu overexpression and clinical predictors of survival in a cohort of 347 patients with primary malignant brain tumors. Cancer Invest 22:537–544PubMedCrossRef

12.

Gilbertson RJ, Wickramasinghe C, Herman R, Balaji V, Hunt D, Jones-Wallace D, Crolla J, Perry RH, Lunec J, Pearson AD, Ellison D (2001) Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 85:705–712PubMedCrossRef

13.

Pellikainen J, Naukkarinen A, Ropponen K, Rummukainen J, Kataja V, Kellokoski J, Eskelinen M, Kosma VM (2004) Expression of HER2 and its association with AP-2 in breast cancer. Eur J Cancer 40:1485–1495PubMedCrossRef

14.

Tateishi M, Teruyoshi I, Mitsudomi T, Kanedo S, Sugimachi K (2004) Prognostic value of c-erbB2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 27:1372–1375

15.

Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Twaddell T, Henderson IC, Norton L (1996) Phase II study of weekly intravenous recombinant humanized anti-p185 HER2 monolclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737–744PubMed

16.

Mineo JF, Bordron A, Quintin-Roué I, Loisel S, Le Ster K, Buhé V, Lagarde N, Berthou C (2004) Recombinant Humanized Anti-HER2/ neu Antibody (Herceptin^®) induces cellular death of glioblastomas. Br J Cancer 91:1195–1199PubMed

17.

Mineo JF, Bordron A, Isabelle QR, Maurage CA, Buhé V, Loisel S, Dubois F, Blond S, Berthou C (2006) Increasing of HER2 membranar density in human glioblastoma U251MG cell line established in a new nude mice model. J Neurooncol 76:249–255PubMedCrossRef

18.

Staverosky JA, Muldoon LL, Guo S, Evans AJ, Neuwelt AJ, Clinton GM (2005) Herstatin, an autoinhibitor of the epidermal growth factor receptor family, blocks the intracranial growth of glioblastoma. Clin Cancer Res 11:335–340PubMed

19.

Forseen SE, Potti A, Koka V, Koch M, Fraiman G, Levitt R (2002) Identification and relationship of HER2/neu overexpression to short-term mortality in primary malignant brain tumors. Anticancer Res 22:1599–1602PubMed

20.

Kaplan EL, Meier P (1958) Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRef

21.

Kleihues P, Ohgaki H (1999) Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-oncol 1:44–51PubMedCrossRef

22.

Fujisawa H, Reis RM, Nakamura M, Colella S, Yonekawa Y, Kleihues P, Ohgaki H (2000) Loss of heterozygosity on chromosome 10 is more extensive in primary (De Novo) than in secondary glioblastomes. Lab Invest 80:65–71PubMedCrossRef

23.

Press MF, Cordon-Cardo C, Slamon DJ (1990) Expression of the HER2/neu proto-oncogene in normal adult and fetal tissues. Oncogene 5:953–962PubMed

24.

Kristt DA, Yarden Y (1996) Differences between phosphotyrosine accumulation and neu/erbB-2 receptor expression in astrocytic proliferative processes: implication for glial oncogenesis. Cancer 78:1272–1283PubMedCrossRef

25.

Bian XW, Shi JQ, Liu FX (2000) Pathologic significance of proliferative activity and oncoprotein expression in astrocytic tumors. Anal Quant Cytol Histol 22:429–437PubMed

26.

Harwerth IM, Wels W, Schlegel J, Müller M, Hynes NE (1993) Monoclonal antibodies directed to the erbB2 receptor inhibit in vivo tumour cell growth. Br J cancer 68:1140–1145PubMed

27.

Sliwkowski M, Lofgren J, Lewis G, Hostaling T, Fendly B, Fox J (1999) Nonclinical studies addressing the mechanism of action of trastuzumab. Semin Oncol 26:60–70PubMed

28.

Vajkoczy P, Schilling L, Ullrich A, Schmiedek P, Menger M (1998) Characterization of angiogenesis and microcirculation of high-grade glioma: an intravital multifluorescence microscopic approach in the athymic nude mouse. J Cereb Blood Flow Metab 18:510–520PubMedCrossRef

29.

Dietzmann K, Von Bossanyi P (1994) Coexpression of epidermal groth factor receptor protein and c-erbB2 oncoprotein in human astrocytic tumors. Zentralbl pathol 140:335–341PubMed

30.

Westphal M, Meima L, Szonyi E, Lofgren L, Meissner H, Hamel W, Nikolics K, Sliwkowski M (1997) Heregulins and the Erb-2/3/4 receptors in gliomas. J Neurooncol 35:335–346PubMedCrossRef

31.

Büchler P, Reber H, Büchler M, Roth M, Büchler M, Friess H, Isacoff W, Hines O (2001) Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody. J Gastrointest Surg 5:139–146PubMedCrossRef

32.

Lang FF, Miller DC, Koslow M, Newcomb EW (1994) Pathways leading to glioblastoma multiforme : a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 81:427–436PubMedCrossRef

33.

Nozaki M, Tada M, Kobayashi H, Zhang CL, Sawamura Y, Abe H, Ishii N, Van Meir EG (1999) Roles of the functional loss of P53 and other genes in astrocytoma tumorigenesis and progression. Neuro-oncology 1:124–137PubMed

34.

Thomas CY, Chouinard M, Cox M, Parson S, Stalling-Mann M, Garcia R, Jove R, Wharen R (2003) Spontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells. Int J Cancer 104:19–27PubMedCrossRef

35.

Haapasalo H, Hyytinen E, Sallinen P, Helin H, Kallioniemi OP, Isola J (1996) C-erbB2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization. Br J Cancer 73:620–623PubMed

36.

Keles GE, Anderson B, Berger MS (1999) The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol 52:371–379PubMedCrossRef

Titel: Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma
verfasst von: Jean-François Mineo
Anne Bordron
Marc Baroncini
Claude-Alain Maurage
Carole Ramirez
Rose-Mary Siminski
Christian Berthou
Phong Dam Hieu
Publikationsdatum: 01.12.2007
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2007
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-007-9424-1

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Findings

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2007

Progressive multifocal leukoencephalopathy in a patient with marginal zone B-cell lymphoma

Multifocal strokes as the presentation of occult lung cancer

Chemotherapy improves the survival of patients with choroid plexus carcinoma: a meta-analysis of individual cases with choroid plexus tumors

Dual targeting of IGF-1R and PDGFR inhibits proliferation in high-grade gliomas cells and induces radiosensitivity in JNK-1 expressing cells

No association of MDM2 SNP309 with risk of glioblastoma and prognosis